Ocugen Inc (OCGN)

$1.25 +0.02 (1.63%)
Market Cap 416.38M
Revenue (ttm) 4.41M
Net Income (ttm) -67.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,538.55%
Debt to Equity Ratio 5.03
Volume 3,549,100
Avg Vol 7,033,054
Day's Range N/A - N/A
Shares Out 338.52M
Stochastic %K 53%
Beta 2.18
Analysts Strong Sell
Price Target $10.22

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 328 4701
Address:
11 Great Valley Parkway, Malvern, United States
VaccineJunkies
VaccineJunkies Aug. 4 at 11:45 AM
$OCGN
0 · Reply
VaccineJunkies
VaccineJunkies Aug. 4 at 11:41 AM
$OCGN I got an email about voting in this upcoming proposal to increase the shares. By what 250 million or something? Can anybody explain? Is this already priced in because they're going to get away with it and my shares are going to be diluted. I own 10,000 and I'm feeling like that's going to hurt. Please let it already be priced in. I voted no
1 · Reply
sidsai
sidsai Aug. 4 at 11:37 AM
$OCGN Why won't the company exist?
0 · Reply
Bio_Apple
Bio_Apple Aug. 4 at 11:31 AM
$OCGN Today is the last chance to buy at a good price; tomorrow prices will rise sharply. Please bookmark this post 😉
0 · Reply
Madpatsy
Madpatsy Aug. 4 at 11:19 AM
$OCGN
0 · Reply
ChurxyChurx
ChurxyChurx Aug. 4 at 8:22 AM
$OCGN $PSNL the 2 most pathetic joke stocks ever. bankrupt shits. GIVE ME MY MONEY BACK
0 · Reply
nickw34q
nickw34q Aug. 4 at 7:38 AM
$OCGN good morning 🌅
0 · Reply
SmoldyShatStone
SmoldyShatStone Aug. 4 at 4:15 AM
$OCGN don’t forget the OcuTurds are excited about adding another 250M shares that Shanky is requesting to dilute them into the abyss and make them the next “BIIIIIIIIIG PHARMAAAAAAAA” 😂😂 love the Shanksters so damn much!! Shanky is working diligently for you baggies 😂😂😂
0 · Reply
LadyBABA
LadyBABA Aug. 4 at 3:40 AM
$OCGN guys, only down 98.9% all time, you coulda bought Apple
1 · Reply
ChiefNC9
ChiefNC9 Aug. 4 at 3:22 AM
$OCGN
0 · Reply
Latest News on OCGN
Ocugen to Participate in Upcoming August Investor Conferences

Jul 31, 2026, 7:02 AM EDT - 4 days ago

Ocugen to Participate in Upcoming August Investor Conferences

Ocugen Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 4 days ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Jul 30, 2026, 8:00 AM EDT - 4 days ago

Ocugen Proxy statement: Proxy filing

Ocugen granted RMAT designation for OCU410

2026-07-29T11:51:46.000Z - 5 days ago

Ocugen granted RMAT designation for OCU410

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Jul 29, 2026, 7:01 AM EDT - 6 days ago

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Jul 28, 2026, 4:01 PM EDT - 6 days ago

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen Proxy statement: Proxy filing

Jul 20, 2026, 8:00 AM EDT - 14 days ago

Ocugen Proxy statement: Proxy filing

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

2026-07-13T11:35:36.000Z - 22 days ago

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Jul 13, 2026, 7:02 AM EDT - 22 days ago

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Jul 10, 2026, 10:00 AM EDT - 24 days ago

Ocugen Transcript: Piper Sandler Virtual Ophthalmology Day

Ocugen to Participate in Upcoming July Industry Conferences

Jul 1, 2026, 7:00 AM EDT - 4 weeks ago

Ocugen to Participate in Upcoming July Industry Conferences

Ocugen Transcript: AGM 2026

Jun 11, 2026, 8:00 AM EDT - 7 weeks ago

Ocugen Transcript: AGM 2026

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Jun 4, 2026, 2:30 PM EDT - 2 months ago

Ocugen Transcript: Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Jun 2, 2026, 7:03 AM EDT - 2 months ago

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Ocugen price target lowered to $11 from $12 at Canaccord

2026-05-27T11:37:17.000Z - 2 months ago

Ocugen price target lowered to $11 from $12 at Canaccord

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 10:30 AM EDT - 2 months ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 14, 2026, 4:30 PM EDT - 2 months ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

May 13, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

Ocugen reports Q1 EPS (6c), consensus (5c)

2026-05-05T13:15:52.000Z - 3 months ago

Ocugen reports Q1 EPS (6c), consensus (5c)

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:32 AM EDT - 3 months ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings Call Transcript: Q1 2026

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Earnings release: Q1 2026

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 3 months ago

Ocugen Quarterly report: Q1 2026

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

May 5, 2026, 8:12 AM EDT - 3 months ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

Ocugen announces private offering of $115M of convertible senior notes

2026-05-04T20:16:05.000Z - 3 months ago

Ocugen announces private offering of $115M of convertible senior notes

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

May 4, 2026, 4:01 PM EDT - 3 months ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 29, 2026, 7:02 AM EDT - 3 months ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 23, 2026, 7:02 AM EDT - 3 months ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Ocugen Proxy statement: Proxy filing

Ocugen completes dosing in GARDian3 trial

2026-04-01T11:56:15.000Z - 4 months ago

Ocugen completes dosing in GARDian3 trial

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Apr 1, 2026, 7:02 AM EDT - 4 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T13:20:15.000Z - 4 months ago

Ocugen price target raised to $12 from $8 at Noble Capital

Ocugen price target raised to $10 from $7 at H.C. Wainwright

2026-03-25T10:11:21.000Z - 4 months ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Ocugen Transcript: Study update

Ocugen Press release: Study update

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Ocugen Press release: Study update

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

2026-03-24T11:55:27.000Z - 4 months ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 24, 2026, 7:45 AM EDT - 4 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Mar 23, 2026, 7:02 AM EDT - 4 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Ocugen initiated with a Buy at Canaccord

2026-03-17T11:30:27.000Z - 5 months ago

Ocugen initiated with a Buy at Canaccord

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:40:53.000Z - 5 months ago

Ocugen initiated with an Outperform at Oppenheimer

Ocugen price target raised to $22 from $15 at Lucid Capital

2026-03-11T10:10:53.000Z - 5 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

Ocugen Earnings Call Transcript: Q4 2025

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

Ocugen Annual report: Q4 2025

Ocugen Earnings release: Q4 2025

Mar 4, 2026, 8:30 AM EST - 5 months ago

Ocugen Earnings release: Q4 2025

Ocugen reports Q4 EPS (6c), consensus (6c)

2026-03-04T13:28:15.000Z - 5 months ago

Ocugen reports Q4 EPS (6c), consensus (6c)

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 8:15 AM EST - 5 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Mar 2, 2026, 7:02 AM EST - 5 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Feb 9, 2026, 7:02 AM EST - 6 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 23, 2026, 8:00 AM EST - 6 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 6 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Transcript: Study result

Ocugen Press release: Study result

Jan 15, 2026, 8:30 AM EST - 7 months ago

Ocugen Press release: Study result

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 15, 2026, 8:15 AM EST - 7 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 13, 2026, 7:00 AM EST - 7 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 12, 2026, 6:30 AM EST - 7 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Jan 9, 2026, 7:02 AM EST - 7 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Dec 10, 2025, 9:20 AM EST - 8 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 20, 2025, 7:02 AM EST - 9 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

Ocugen Earnings Call Transcript: Q3 2025

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

Ocugen Quarterly report: Q3 2025

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 8:30 AM EST - 9 months ago

Ocugen Earnings release: Q3 2025

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Nov 5, 2025, 6:30 AM EST - 9 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 10 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 25, 2025, 9:30 AM EDT - 11 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 15, 2025, 6:03 AM EDT - 11 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Sep 2, 2025, 7:02 AM EDT - 1 year ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 13, 2025, 6:27 AM EDT - 1 year ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 12, 2025, 3:45 PM EDT - 1 year ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 1 year ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q2 2025

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q2 2025

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q2 2025

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Aug 1, 2025, 8:25 AM EDT - 1 year ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 18, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jul 17, 2025, 6:30 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Ocugen To Present at BIO International Convention 2025

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

VaccineJunkies
VaccineJunkies Aug. 4 at 11:45 AM
$OCGN
0 · Reply
VaccineJunkies
VaccineJunkies Aug. 4 at 11:41 AM
$OCGN I got an email about voting in this upcoming proposal to increase the shares. By what 250 million or something? Can anybody explain? Is this already priced in because they're going to get away with it and my shares are going to be diluted. I own 10,000 and I'm feeling like that's going to hurt. Please let it already be priced in. I voted no
1 · Reply
sidsai
sidsai Aug. 4 at 11:37 AM
$OCGN Why won't the company exist?
0 · Reply
Bio_Apple
Bio_Apple Aug. 4 at 11:31 AM
$OCGN Today is the last chance to buy at a good price; tomorrow prices will rise sharply. Please bookmark this post 😉
0 · Reply
Madpatsy
Madpatsy Aug. 4 at 11:19 AM
$OCGN
0 · Reply
ChurxyChurx
ChurxyChurx Aug. 4 at 8:22 AM
$OCGN $PSNL the 2 most pathetic joke stocks ever. bankrupt shits. GIVE ME MY MONEY BACK
0 · Reply
nickw34q
nickw34q Aug. 4 at 7:38 AM
$OCGN good morning 🌅
0 · Reply
SmoldyShatStone
SmoldyShatStone Aug. 4 at 4:15 AM
$OCGN don’t forget the OcuTurds are excited about adding another 250M shares that Shanky is requesting to dilute them into the abyss and make them the next “BIIIIIIIIIG PHARMAAAAAAAA” 😂😂 love the Shanksters so damn much!! Shanky is working diligently for you baggies 😂😂😂
0 · Reply
LadyBABA
LadyBABA Aug. 4 at 3:40 AM
$OCGN guys, only down 98.9% all time, you coulda bought Apple
1 · Reply
ChiefNC9
ChiefNC9 Aug. 4 at 3:22 AM
$OCGN
0 · Reply
LadyBABA
LadyBABA Aug. 4 at 1:32 AM
$OCGN can’t believe this company still exists 😂🤣 blast from the past
3 · Reply
BeMaWe
BeMaWe Aug. 3 at 9:47 PM
$OCGN Think WE would need some more of these green days. Still soo deeply undervalued, If the sciences is working and evidence in form of FDA approval would kick in... Damm, this one lets you dreaming. Patience - still some months to HOLD 💎🚀🦄🌴☀️
1 · Reply
ExploringTrades
ExploringTrades Aug. 3 at 9:45 PM
Have you seen the Ebola outbreak news this weekend?? 🤯 Make sure to put VRAX onto your watchlist 💎 Ticker VRAX is one of the tiniest float bio-techs that great cash position and Peptides against Ebola! I accumulated a huge amount of shares because of the recent Ebola outbreak. Numbers are rising concerningly fast. The right PR and it could see a big squeeze like the last time we saw an outbreak! $OCGN On my radar
0 · Reply
ColdSmkskier
ColdSmkskier Aug. 3 at 9:35 PM
$OCGN my god - this is pinned down tighter that a 13year old girl at Mar a Lago. 1000%
2 · Reply
BigMoves1672
BigMoves1672 Aug. 3 at 9:05 PM
$OCGN
2 · Reply
dgiudice
dgiudice Aug. 3 at 9:05 PM
$OCGN Could this guy, Shankar be the 'shanky' that all these Aholes keep saying is running a scam? LOL I guess the patients are all in on it, too, as are the two (so far) RMAT designations three of their disruptive products.
1 · Reply
CasaDePapel
CasaDePapel Aug. 3 at 8:43 PM
$OCGN if Shanky wants money to spend on his scam project let Him find a few partners, and not spend retail money
0 · Reply
CasaDePapel
CasaDePapel Aug. 3 at 8:41 PM
$OCGN voted NO and NO on both shankys scam wishes!
0 · Reply
WayLoSellHi
WayLoSellHi Aug. 3 at 8:23 PM
$OCGN A green day is a green day good to see it Ocufam 💚
0 · Reply
Gr8peApe
Gr8peApe Aug. 3 at 7:38 PM
$OCGN
0 · Reply
HowULuvThis
HowULuvThis Aug. 3 at 7:36 PM
$OCGN $ES_F Heck of a trending day on ES👊😎👊
0 · Reply
Pit1908
Pit1908 Aug. 3 at 7:16 PM
$OCGN +$20,00 💚💯 Behind every breakthrough is a patient, a family, and a story, reminding us why innovation matters. At Ocugen, we remain committed and are humbled by the potential impact our science can have on people's lives. Moments like these reinforce our purpose, to keep pushing the boundaries of what’s possible and create hope for patients and families around the world!🌈🧬🌍🌎🌏 ~Shankar Musunuri
0 · Reply